These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31660310)

  • 21. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reversal agents for severe bleeding associated with direct oral anticoagulants].
    Giubilato S; Lucà F; Di Fusco SA; Amico F; Colivicchi F; Gulizia MM
    G Ital Cardiol (Rome); 2022 Oct; 23(10):734-745. PubMed ID: 36169124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific antidotes in development for reversal of novel anticoagulants: a review.
    Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.
    Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B
    J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis.
    Rodrigues AO; David C; Ferreira JJ; Pinto FJ; Costa J; Caldeira D
    Thromb Res; 2020 Dec; 196():291-296. PubMed ID: 32949961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of direct oral anticoagulants.
    Almegren M
    Vasc Health Risk Manag; 2017; 13():287-292. PubMed ID: 28769570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
    Chaudhary R; Singh A; Chaudhary R; Bashline M; Houghton DE; Rabinstein A; Adamski J; Arndt R; Ou NN; Rudis MI; Brown CS; Wieruszewski ED; Wanek M; Brinkman NJ; Linderbaum JA; Sorenson MA; Atkinson JL; Thompson KM; Aiyer AN; McBane RD
    JAMA Netw Open; 2022 Nov; 5(11):e2240145. PubMed ID: 36331504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.
    Kustos SA; Fasinu PS
    Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31618893
    [No Abstract]   [Full Text] [Related]  

  • 30. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding.
    Moia M; Squizzato A
    Intern Emerg Med; 2019 Nov; 14(8):1233-1239. PubMed ID: 31446606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.
    Siegal DM
    J Thromb Thrombolysis; 2015 Apr; 39(3):395-402. PubMed ID: 25586208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct oral anticoagulant reversal: how, when and issues faced.
    Dzeshka MS; Pastori D; Lip GYH
    Expert Rev Hematol; 2017 Nov; 10(11):1005-1022. PubMed ID: 28901221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
    Weitz JI
    Semin Respir Crit Care Med; 2017 Feb; 38(1):40-50. PubMed ID: 28208197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
    Ageno W; Büller HR; Falanga A; Hacke W; Hendriks J; Lobban T; Merino J; Milojevic IS; Moya F; van der Worp HB; Randall G; Tsioufis K; Verhamme P; Camm AJ
    Thromb Haemost; 2016 Nov; 116(6):1003-1010. PubMed ID: 27488232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro
    Oberladstätter D; Schlimp CJ; Zipperle J; Osuchowski MF; Voelckel W; Grottke O; Schöchl H
    J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.
    Lu G; Lin J; Bui K; Curnutte JT; Conley PB
    Res Pract Thromb Haemost; 2020 Nov; 4(8):1282-1294. PubMed ID: 33313467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies.
    Raimondi P; Hylek EM; Aronis KN
    Curr Pharm Des; 2017; 23(9):1406-1423. PubMed ID: 27917717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds.
    Spyropoulos AC; Hartaigh BÓ; Cao Z; Caberwal H; Lipkin C; Petrini M; Wang C
    Clin Appl Thromb Hemost; 2022; 28():10760296221110568. PubMed ID: 35792949
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
    Gibler WB; Racadio JM; Hirsch AL; Roat TW
    Crit Pathw Cardiol; 2019 Sep; 18(3):143-166. PubMed ID: 31348075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Andexanet Alfa and its Clinical Application.
    Noordergraaf FA; Alings M
    Heart Int; 2020; 14(1):20-23. PubMed ID: 36277667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.